LR-CHOP-21 regimen

Jump to navigation Jump to search

WikiDoc Resources for LR-CHOP-21 regimen

Articles

Most recent articles on LR-CHOP-21 regimen

Most cited articles on LR-CHOP-21 regimen

Review articles on LR-CHOP-21 regimen

Articles on LR-CHOP-21 regimen in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on LR-CHOP-21 regimen

Images of LR-CHOP-21 regimen

Photos of LR-CHOP-21 regimen

Podcasts & MP3s on LR-CHOP-21 regimen

Videos on LR-CHOP-21 regimen

Evidence Based Medicine

Cochrane Collaboration on LR-CHOP-21 regimen

Bandolier on LR-CHOP-21 regimen

TRIP on LR-CHOP-21 regimen

Clinical Trials

Ongoing Trials on LR-CHOP-21 regimen at Clinical Trials.gov

Trial results on LR-CHOP-21 regimen

Clinical Trials on LR-CHOP-21 regimen at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on LR-CHOP-21 regimen

NICE Guidance on LR-CHOP-21 regimen

NHS PRODIGY Guidance

FDA on LR-CHOP-21 regimen

CDC on LR-CHOP-21 regimen

Books

Books on LR-CHOP-21 regimen

News

LR-CHOP-21 regimen in the news

Be alerted to news on LR-CHOP-21 regimen

News trends on LR-CHOP-21 regimen

Commentary

Blogs on LR-CHOP-21 regimen

Definitions

Definitions of LR-CHOP-21 regimen

Patient Resources / Community

Patient resources on LR-CHOP-21 regimen

Discussion groups on LR-CHOP-21 regimen

Patient Handouts on LR-CHOP-21 regimen

Directions to Hospitals Treating LR-CHOP-21 regimen

Risk calculators and risk factors for LR-CHOP-21 regimen

Healthcare Provider Resources

Symptoms of LR-CHOP-21 regimen

Causes & Risk Factors for LR-CHOP-21 regimen

Diagnostic studies for LR-CHOP-21 regimen

Treatment of LR-CHOP-21 regimen

Continuing Medical Education (CME)

CME Programs on LR-CHOP-21 regimen

International

LR-CHOP-21 regimen en Espanol

LR-CHOP-21 regimen en Francais

Business

LR-CHOP-21 regimen in the Marketplace

Patents on LR-CHOP-21 regimen

Experimental / Informatics

List of terms related to LR-CHOP-21 regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords:R2CHOP regimen ;Revlimid-Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone Regimen

Overview

LR-CHOP-21 regimen refers to a chemotherapeutic regimen consisting of lenalidomide (revlimid), rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolonegiven every 21 days has high activity in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1]

Regimen

L/RLenalidomide (Revlimid)

RRituximab

CCyclophosphamide

HDoxorubicin (Hydroxydoxorubicin Hydrochloride)

OVincristine (Oncovin)

PPrednisolone

Indications

References

  1. 1.0 1.1 Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G; et al. (2014). "Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial". Lancet Oncol. 15 (7): 730–7. doi:10.1016/S1470-2045(14)70191-3. PMID 24831981.